Flex Pharma Educates Athletes about Breakthrough Discovery
Flex Pharma, Inc. (NASDAQ: FLKS), a company developing innovative and proprietary treatments for exercise-associated muscle cramps, nocturnal leg cramps, and spasms associated with severe neuromuscular conditions, has launched a print and digital campaign with the objective to build awareness and educate consumers that the root cause of muscle cramping is the nerve, not the muscle. To date, the Company’s findings and its development of the first scientifically proven formula to treat and prevent muscle cramps have appeared in Outside Magazine, Competitor, Runner’s World, Bicycling, and Running Times, among others. “The excitement around this scientific breakthrough is remarkable. People in the endurance community and beyond are fascinated and encouraged by the genius discovery from Nobel Prize-winner and company founder, Dr. Rod MacKinnon," said Marina Hahn, President Consumer. “We know how painful cramping can be to those with an active lifestyle, and will continue to partner with influential media to spread the news of our scientific discovery throughout the year.” Flex Pharma’s educational effort and awareness campaign around athletes participating in high intensity sports has included participation in a variety of endurance events, including IRONMAN Boulder, Leadville Trail 100 MTB and Leadville Trail 100 Run. The Company also will appear at the IRONMAN World Championships presented by GoPro and IRONMAN Sports Medicine Conference in October prior to a consumer product being available to the public in 2016. The goal of Flex Pharma’s efforts is to take athletes beyond the traditional mindset that exercise-associated muscle cramps are caused by a problem with the muscle. Instead, the Company is highlighting the real culprit: the nerve. No matter what conditions impact muscle performance in the first place – heat, fatigue, dehydration, electrolyte loss, reduced blood flow – the cramping of a muscle is triggered by the excessive firing of motor neurons in the spinal cord. The muscle then bunches up and is unable to relax, resulting in loss of motor control and pain. Drawing on his Nobel Prize winning research, Dr. MacKinnon designed a sports beverage to stimulate sensory fibers and prevent the motor nerves from becoming hyper-excited, greatly reducing the risk of cramping. This novel mechanism of chemical neurostimulation is leading to a new category in nutrition: Neuromuscular Performance – a focus on creating and sustaining the right nervous system conditions in the body for optimal neuromuscular balance. About Flex Pharma Flex Pharma, Inc. is a biotechnology company that is developing innovative and proprietary treatments for exercise-associated muscle cramps, nocturnal leg cramps, and spasms associated with severe neuromuscular conditions. In three randomized, blinded, placebo-controlled, cross-over studies, Flex Pharma's proprietary treatment has shown a statistically significant reduction in the intensity of muscle cramps in healthy normal volunteers. Flex Pharma was founded by National Academy of Sciences members Rod MacKinnon, M.D. (2003 Nobel Laureate), and Bruce Bean, Ph.D., recognized leaders in the fields of ion channels and neurobiology, along with Chairman and Chief Executive Officer Christoph Westphal, M.D., Ph.D. Individuals can follow the Company on Twitter (@flexpharma) and the Company's website (http://ir.flex-pharma.com/) to see the latest progress of the Company's pre-launch activities for its consumer product to prevent and treat exercise-associated muscle cramps.
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, our plans to develop and commercialize our consumer products and the future availability of our consumer products. These forward-looking statements are based on management's expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation: the status, timing, costs, results and interpretation of our clinical studies; our ability to develop and commercialize our consumer products; anticipated positioning and product attributes of our consumer products; results of early clinical studies as indicative of the results of future trials; and other factors discussed in greater detail under the heading "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2014 and subsequent filings with the Securities and Exchange Commission (SEC). You are encouraged to read our filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.